Inventor · disambiguated record
Jean-Rene Authelin
Also filed as: AUTHELIN JEAN-REN E · AUTHELIN JEAN-RENE
5 granted patents·3 pending applications·109 citations·filing 1995–2015
79Inventor score
Top patents by PatentIndex Score
8 records- 0189US6022985AProcess for the preparation of 4-acetoxy-2α-benzoyloxy-5β, 20-epoxy-1, 7β-10β-trihydroxy-9-oxo-tax-11-en-13α-yl(2R,3S)-3-tert-b utoxy-carbonYlamino-2-hydroxy-3-phenylpropionate trihydrateRHONE POULENC RORER SA·Filed 1995·Granted Feb 8, 2000·81 cites·5 claims
- 0271US6641063B2Milling process for the production of finely milled medicinal substancesAVENTIS PHARMA LTD·Filed 2001·Granted Nov 4, 2003·10 cites·12 claims
- 0367US6002022AMethod for preparing 4, 10-diacetoxy-2α-benzoyloxy-5β, 20-Epoxy-1, 7β-dihydroxy-9-oxo-tax-11-en-13α-yl(2R,3S)-3-benzoylamino-2-h ydroxy-3-phenylpropionate trihydrateRHONE POULENC RORER SA·Filed 1996·Granted Dec 14, 1999·16 cites·8 claims
- 0452US2010197776A1Direct dissolution of docetaxel in a solvent in polysorbate 80AVENTIS PHARMA SA·Filed 2009·Application pending·0 cites
- 0541US6150541A4,10-β-diacetoxy-2α-benzoyloxy-5β,20-epoxy-1-hydroxy-9-oxo-19-norcyclopropa[g]t ax-11-en-13α-yl (2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate dihydrate and its process of preparationAVENTIS PHARMA SA·Filed 1998·Granted Nov 21, 2000·2 cites·6 claims
- 0637US2006002864A1Milling process for the production of finely milled medicinal substancesAVENTIS PHARMA LTD·Filed 2005·Application pending·0 cites
- 0735US2015119391A1Anti-tumoral composition comprising the compound 1-(6--1,3-benzothiazol-2-yl)-3-(2-morpholin-4-ylethyl)ureaSANOFI SA·Filed 2015·Application pending·0 cites
- 0833US7041318B2Milling process for the production of finely milled medicinal substancesAVENTIS PHARMA LTD·Filed 2001·Granted May 9, 2006·0 cites·8 claims
Join the waitlist — get patent alerts
Get an alert when Jean-Rene Authelin files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →